[PRNewswire] PharmaZell and Novasep enter into exclusive negotiations in new

최정환 입력 2021. 9. 17. 10:04
글자크기 설정 파란원을 좌우로 움직이시면 글자크기가 변경 됩니다.

이 글자크기로 변경됩니다.

(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.

drive to create a technology-driven leader for complex small molecules and ADCs of global scale

(RAUBLING, Germany and LYON, France, Sept. 16, 2021 PRNewswire=연합뉴스) PharmaZell, the German producer of highly resilient and specialty APIs, and France-based Novasep, a leading CDMO focused on complex small molecules and ADCs have entered into exclusive negotiations to create a leading European platform in the attractive API manufacturing and CDMO space with a complementary set of differentiated technologies and highly diversified base of blue-chip pharma and biotech customers.

Novasep is a leading CDMO player developing and manufacturing complex small molecules predominantly for pharma and biotech customers. The company leverages a wide range of differentiated technologies including high energy and cryogenic chemistries and industrial scale chromatography. It is a world leader in ADC and HPAPI, fast-growing targeted cancer therapy segments.

Novasep's capabilities are highly complementary to PharmaZell's expertise in the manufacturing of complex APIs requiring special handling procedures or technologies. Combining the two businesses would create a leading, highly diversified, and highly differentiated API manufacturing and CDMO platform. The combined business would be able to draw from a comprehensive and broad technology suite for complex molecules and a global production footprint to support pharma and biotech customers over the complete lifecycle of a drug. The combined business would generate nearly €500m of revenues and employ close to 2,000 employees across seven production and R&D sites in Europe (Germany, France and Italy), two sites in India and one in the US.

The proposed transaction would be backed by PharmaZell's current majority shareholder Bridgepoint. Bridgepoint Group PLC is the world's leading quoted private assets growth investor focused on the middle-market with €27 billion AUM and a local presence in the US, Europe and China.

The proposed acquisition remains subject to the fulfilment of customary conditions precedent for this type of transaction including the information and consultation of works councils and other regulatory approvals.

The Press release is available in pdf.

Photo - https://mma.prnewswire.com/media/1628012/Novasep_PharmaZell.jpg

PR PharmaZell Novasep

Logo - https://mma.prnewswire.com/media/1628011/Novasep_Passion_Smart_Processes_Logo.jpg


PDF - https://mma.prnewswire.com/media/1628027/PharmaZell_Novasep_ENG.pdf

Contact details:


Source: Novasep

[편집자 주] 본고는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았음을 밝혀 드립니다.


출처 : PRNewswire 보도자료

저작권자(c)연합뉴스. 무단전재-재배포금지

이 기사에 대해 어떻게 생각하시나요?